Overview

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

RATIONALE: rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and best dose of rucaparib and to see how well it works in treating patients with locally advanced or metastatic breast cancer or advanced ovarian cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Cancer Research UK

Treatments:

Rucaparib